202 related articles for article (PubMed ID: 25381575)
21. Alzheimer's disease and amyloid: culprit or coincidence?
Skaper SD
Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
[TBL] [Abstract][Full Text] [Related]
22. Fuzhisan Ameliorates the Memory Deficits in Aged SAMP8 Mice via Decreasing Aβ Production and Tau Hyperphosphorylation of the Hippocampus.
Zhang ZX; Zhao RP; Wang DS; Li YB
Neurochem Res; 2016 Nov; 41(11):3074-3082. PubMed ID: 27518086
[TBL] [Abstract][Full Text] [Related]
23. Immunolocalization of Tom1 in relation to protein degradation systems in Alzheimer's disease.
Makioka K; Yamazaki T; Takatama M; Ikeda M; Murayama S; Okamoto K; Ikeda Y
J Neurol Sci; 2016 Jun; 365():101-7. PubMed ID: 27206884
[TBL] [Abstract][Full Text] [Related]
24. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.
An WL; Cowburn RF; Li L; Braak H; Alafuzoff I; Iqbal K; Iqbal IG; Winblad B; Pei JJ
Am J Pathol; 2003 Aug; 163(2):591-607. PubMed ID: 12875979
[TBL] [Abstract][Full Text] [Related]
26. Different Populations of Human Locus Ceruleus Neurons Contain Heavy Metals or Hyperphosphorylated Tau: Implications for Amyloid-β and Tau Pathology in Alzheimer's Disease.
Pamphlett R; Kum Jew S
J Alzheimers Dis; 2015; 45(2):437-47. PubMed ID: 25547633
[TBL] [Abstract][Full Text] [Related]
27. Untangling amyloid-β, tau, and metals in Alzheimer's disease.
Savelieff MG; Lee S; Liu Y; Lim MH
ACS Chem Biol; 2013 May; 8(5):856-65. PubMed ID: 23506614
[TBL] [Abstract][Full Text] [Related]
28. Altered distribution of RhoA in Alzheimer's disease and AbetaPP overexpressing mice.
Huesa G; Baltrons MA; Gómez-Ramos P; Morán A; García A; Hidalgo J; Francés S; Santpere G; Ferrer I; Galea E
J Alzheimers Dis; 2010; 19(1):37-56. PubMed ID: 20061625
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
Chu J; Lauretti E; Craige CP; Praticò D
J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
[TBL] [Abstract][Full Text] [Related]
30. Protein aggregation in Alzheimer's disease: Aβ and τ and their potential roles in the pathogenesis of AD.
Thal DR; Fändrich M
Acta Neuropathol; 2015 Feb; 129(2):163-5. PubMed ID: 25600324
[No Abstract] [Full Text] [Related]
31. Factors affecting the GABAergic synapse function in Alzheimer's disease: Focus on microRNAs.
Rivera J; Sharma B; Torres MM; Kumar S
Ageing Res Rev; 2023 Dec; 92():102123. PubMed ID: 37967653
[TBL] [Abstract][Full Text] [Related]
32. Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins).
Bramblett GT; Trojanowski JQ; Lee VM
Lab Invest; 1992 Feb; 66(2):212-22. PubMed ID: 1735956
[TBL] [Abstract][Full Text] [Related]
33. Mouse models of Alzheimer's disease: the long and filamentous road.
Phinney AL; Horne P; Yang J; Janus C; Bergeron C; Westaway D
Neurol Res; 2003 Sep; 25(6):590-600. PubMed ID: 14503012
[TBL] [Abstract][Full Text] [Related]
34. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.
Shin MK; Kim HG; Baek SH; Jung WR; Park DI; Park JS; Jo DG; Kim KL
Neurobiol Aging; 2014 May; 35(5):990-1001. PubMed ID: 24268884
[TBL] [Abstract][Full Text] [Related]
35. Quercetin reduces eIF2α phosphorylation by GADD34 induction.
Hayakawa M; Itoh M; Ohta K; Li S; Ueda M; Wang MX; Nishida E; Islam S; Suzuki C; Ohzawa K; Kobori M; Inuzuka T; Nakagawa T
Neurobiol Aging; 2015 Sep; 36(9):2509-18. PubMed ID: 26070242
[TBL] [Abstract][Full Text] [Related]
36. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
Xie Y; Tan Y; Zheng Y; Du X; Liu Q
J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
[TBL] [Abstract][Full Text] [Related]
37. Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology.
Arendt T; Stieler J; Holzer M
J Neural Transm (Vienna); 2015 Apr; 122(4):531-9. PubMed ID: 25480630
[TBL] [Abstract][Full Text] [Related]
38. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
Hardy J; Selkoe DJ
Science; 2002 Jul; 297(5580):353-6. PubMed ID: 12130773
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
40. Tau aggregation and its interplay with amyloid-β.
Nisbet RM; Polanco JC; Ittner LM; Götz J
Acta Neuropathol; 2015 Feb; 129(2):207-20. PubMed ID: 25492702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
